AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00794677
Drug: ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Blinded study medication (ezetimibe 10 mg in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
Trial: NCT04707742
Drug: Distilled Water
RxNorm normalized name: Distilled Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml distilled water, one minute rinse.
Trial: NCT00314184
Drug: quetiapine fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02215356
Drug: Icotinib with concurrent radiotherapy
RxNorm normalized name: Primatene with ephedrine Pill
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib: 125 mg is administered orally three times per day.
Trial: NCT03223428
Drug: Xermelo
RxNorm normalized name: Xermelo
DrugBank: Telotristat ethyl (DB12095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.
Trial: NCT00800137
Drug: Warfarin or coumadin
RxNorm normalized name: warfarin Oral Tablet [Coumadin]
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be \< 3.0
Trial: NCT01834274
Drug: Fasiglifam (TAK-875)
RxNorm normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam (TAK-875) tablets
Trial: NCT01834274
Drug: Fasiglifam (TAK-875) Placebo
DrugBank: Fasiglifam (DB12491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasiglifam (TAK-875) placebo-matching tablets
Trial: NCT01834274
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin tablets
Trial: NCT01834274
Drug: Sitagliptin Placebo
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin placebo-matching tablets
Trial: NCT01834274
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin tablets
Trial: NCT03119714
Drug: Pemirolast
RxNorm normalized name: Pemirolast
DrugBank: Pemirolast (DB00885)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with pemirolast 200 mg bid for 14-16 days
Trial: NCT02017327
Drug: Monoprost
RxNorm normalized name: dinoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.
Trial: NCT00311974
Drug: Dihydralazine
RxNorm normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02031770
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.
Trial: NCT03961815
Drug: Brazikumab Induction Dose
RxNorm normalized name: human sputum, Bordetella pertussis infected
DrugBank: Brazikumab (DB16115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who met criteria for early termination due to lack of efficacy (rescue treatment criteria) or who did not meet CDAI response at Week 52 in the lead-in study D5121C00001 are considered inadequate/non responders, and will receive IV induction dosing brazikumab at Week 0, Week 4, and Week 8 followed by maintenance dosing of brazikumab subcutaneously every 4 weeks thereafter up to Week 52.
Trial: NCT03961815
Drug: Brazikumab Maintenance Dose
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
DrugBank: Brazikumab (DB16115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders from Lead-In study D5271C00001 who completed requirements through Week 52 and met CDAI response (CDAI score of \< 150 points or CDAI reduction from Baseline of ≥ 100 points) without ongoing rescue treatment at Week 52 in the lead-in study. will receive maintenance dose of brazikumab administered subcutaneously every 4 weeks through Week 52, starting at Week 0. The subcutaneous dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered
Trial: NCT02442063
Drug: Radium Ra 223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles
Trial: NCT02442063
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1
Trial: NCT03904563
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients are treated with Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
Trial: NCT03904563
Drug: concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
Trial: NCT00075478
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00075478
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00075478
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01844674
Drug: Tizanidine
RxNorm normalized name: Tizanidine
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast \>/= 10 hours.
Trial: NCT01844674
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
Trial: NCT00485667
Drug: Moxifloxacin 400mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00054067
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00336973
Drug: efalizumab
RxNorm normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous repeating dose
Trial: NCT00034658
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00687063
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
Trial: NCT02499861
Drug: Decitabine and Genistein
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous Decitabine with oral genistein
Trial: NCT00000299
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01666431
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00763750
Drug: PPX +TMZ+XRT
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
Trial: NCT02171611
Drug: Dabigatran etexilate pellets
RxNorm normalized name: dabigatran etexilate Pellet Product
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02171611
Drug: Dabigatran etexilate powder
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02171611
Drug: Dabigatran etexilate capsule
RxNorm normalized name: Dabigatran Etexilate Capsules
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02009436
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given via nebulizer
Trial: NCT02054897
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once weekly, administrated subcutaneously (s.c. under the skin)
Trial: NCT02682784
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal spray based on naturally occurring hormone, oxytocin.
Trial: NCT03666728
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 was administered 200 mg iv every 3 weeks
Trial: NCT03666728
Drug: BP102
RxNorm normalized name: Buprenorphine/Naloxone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BP102 was administered 15 mg/kg iv every 3 weeks
Trial: NCT02215876
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
Trial: NCT00471523
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00471523
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00363948
Drug: Sitagliptin phosphate
RxNorm normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Trial: NCT00904215
Drug: telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00652366
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
Trial: NCT02305394
Drug: ketamine and propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.
Trial: NCT02305394
Drug: propofol and normal saline
RxNorm normalized name: NS-2359
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol 1.5 mg/kg and normal saline \[weight(kg)×0.3÷10\]ml will be administered to participants separately by intravenous infusion.
Trial: NCT01891994
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration of eltrombopag 150mg/day (75 mg/day for East Asian ancestry) for 6 months
Trial: NCT03351244
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 week treatment period
Trial: NCT00118235
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00118235
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02576938
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT01890642
Drug: 1% buffered lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine placed using Jet Injection
Trial: NCT02576938
Drug: Triamcinolone (Optional)
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered topically
Trial: NCT01718691
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A dose of 375 mg/m\^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
Trial: NCT00492752
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
Trial: NCT02911116
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous Injection
Trial: NCT00640562
Drug: Quetiapine Extended Release
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
Trial: NCT02911116
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous Infusion
Trial: NCT00640562
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
Trial: NCT04018365
Drug: Empagliflozin Tablets
RxNorm normalized name: Empagliflozin Tablets
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The administration is oral administration with water before or after breakfast.
Trial: NCT03625661
Drug: Ferinject
RxNorm normalized name: epinephrine
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferinject 50mg/ml, one injection
Trial: NCT03061032
Drug: Sofosbuvir/Ledipasvir 12W
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks.
Trial: NCT03061032
Drug: Sofosbuvir/Ledipasvir plus Ribavirin 12W
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks.
Trial: NCT03061032
Drug: Sofosbuvir/Ledipasvir 24W
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks.
Trial: NCT03061032
Drug: Sofosbuvir/Ledipasvir plus Ribavirin 24W
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
Trial: NCT06418607
Drug: Venglustat
RxNorm normalized name: Venglustat
DrugBank: Venglustat (DB14966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablet-Route of administration:Oral
Trial: NCT06418607
Drug: Venglustat
RxNorm normalized name: Venglustat
DrugBank: Venglustat (DB14966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Hard Capsule-Route of administration:Oral
Trial: NCT00794157
Drug: Indacaterol 150 μg capsules
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Trial: NCT00794157
Drug: Indacaterol 300 μg capsules
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Trial: NCT01970501
Drug: bucindolol hydrochloride
RxNorm normalized name: bopindolol
DrugBank: Bucindolol (DB12752)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01970501
Drug: metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03632733
Drug: Clotrimazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole cream
Trial: NCT01639092
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir 300mg Daily Oral
Trial: NCT01639092
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir 1 mg daily Oral
Trial: NCT00077961
Drug: CAMPATH (alemtuzumab)
RxNorm normalized name: alemtuzumab Injection [Campath]
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05476159
Drug: Indocyanine green solution
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adequate perfusion was defined as the direct and clear visualization of the fluorescence along the gastric tube, relative to the excised specimen, after an estimated time of 150-180 s after i.v. administration injection
Trial: NCT01841242
Drug: alcoholic povidone iodine
RxNorm normalized name: isopropyl alcohol / povidone-iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01841242
Drug: alcoholic chlorhexidine
RxNorm normalized name: chlorhexidine / isopropyl alcohol
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02404259
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06560814
Drug: Cabergoline plus timed intercourse
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.5 mg tab orally twice weekly (fridays and tuesdays) after meal at night for 24 weeks plus intercourse timed with LH kit
Trial: NCT06560814
Drug: Dydrogesterone plus timed intercourse
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dydrogesterone 10 mg tab orally twice daily from day 5 to day 25 of menstrual cycle for 24 weeks plus intercourse timed with LH kit
Trial: NCT01162460
Drug: Eslicarbazepine acetate (BIA 2-093)
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Week 1 and 2 either 400mg/day Eslicarbazepine acetate (ESL) or 200mg/day Carbamazepine controlled release(CBZ-CR); Week 3 onwards either 800mg/day Eslicarbazepine acetate or 400mg/day CBZ-CR; this dose then to be maintained unless a subject has a seizure.~Subjects experiencing a seizure will have their assigned treatment dose increased to ESL 1200mg/day or CBZ 800mg/day.~Should a subject have another seizure, their assigned treatment is to be increased to ESL 1600mg/day or CBZ 1200mg/day.~Subjects who remain seizure free for 26 weeks at any dose in an Evaluation Period will continue to receive the allocated treatment under double-blind conditions.
Trial: NCT02404259
Drug: lopinavir/ritonavir, atazanavir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06190652
Drug: Chemotherapy combined with immunotherapy
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy：paclitaxel+platinum-based anticancer drugs immunotherapy：anti-PD-1 Immune checkpoint inhibitors
Trial: NCT02829697
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perineural injection.
Trial: NCT00836056
Drug: Cleocin HCl 300 mg capsules
RxNorm normalized name: Cleocin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 300 mg
Trial: NCT01516346
Drug: Isosorbide Dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.